JP2816499B2 - Diabetes treatment - Google Patents
Diabetes treatmentInfo
- Publication number
- JP2816499B2 JP2816499B2 JP27997790A JP27997790A JP2816499B2 JP 2816499 B2 JP2816499 B2 JP 2816499B2 JP 27997790 A JP27997790 A JP 27997790A JP 27997790 A JP27997790 A JP 27997790A JP 2816499 B2 JP2816499 B2 JP 2816499B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- diabetes
- present
- therapeutic agent
- present compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
【発明の詳細な説明】 「産業上の利用分野」 本発明はブシラミンまたはその塩類を有効成分とする
糖尿病治療剤に関する。The present invention relates to a therapeutic agent for diabetes containing bucillamine or a salt thereof as an active ingredient.
「従来技術、発明が解決しようとする課題及び課題を解
決するための手段」 ブシラミンは抗リウマチ剤として医薬品に用いられて
おり、他にも喀痰溶解剤、肝障害抑制剤、抗白内障剤と
して有用であることが報告されている（特公昭56−5388
号、特公昭60−11888号、特公昭62−13922号、特公昭63
−13964号）。"Prior art, problems to be solved by the invention and means for solving the problems" Bucillamine is used in pharmaceuticals as an antirheumatic agent, and is also useful as a sputum dissolving agent, a liver injury inhibitor, and an anticataract agent (Japanese Patent Publication No. 56-5388)
No., JP-B-60-11888, JP-B-62-13922, JP-B-63
No. 13964).
本発明者等は優れた薬効を有する化合物であるブシラ
ミンについて、さらに新しい薬理作用を見つけるべく種
々検討した結果、糖尿病治療剤として有用であることを
見い出した。The present inventors have conducted various studies to find a new pharmacological action for busilamine, which is a compound having excellent medicinal properties, and as a result, have found that it is useful as a therapeutic agent for diabetes.
「発明の構成」 本発明は下記式で示されるブシラミンまたはその塩類
（以下本化合物という）を有効成分とする糖尿病治療剤
に関する。“Constitution of the Invention” The present invention relates to a therapeutic agent for diabetes comprising a bucillamine represented by the following formula or a salt thereof (hereinafter referred to as the present compound) as an active ingredient.
本発明における塩類とは、医薬として許容される塩で
あればよく、ナトリウム塩、カリウム塩等が例として挙
げられる。 The salt in the present invention may be a pharmaceutically acceptable salt, and examples thereof include a sodium salt and a potassium salt.
本化合物が抗リウマチ抗、喀痰溶解剤、肝障害抑制
剤、抗白内障剤として有用であることが報告されてい
る。It has been reported that this compound is useful as an antirheumatic drug, a sputum dissolving agent, a liver damage inhibitor, and an anticataract agent.
本発明者等は、このように医薬として優れた性質を有
する本化合物のさらに新しい薬理作用を見つけるべく種
々検討した結果、糖尿病治療剤として油用であることを
見い出した。The present inventors have conducted various studies to find a newer pharmacological action of the present compound having such excellent properties as a medicament, and as a result, have found that the present compound is for oils as a therapeutic agent for diabetes.
糖尿病に対する約物の有用性を調べる方法として、ス
トレプトゾトシンで惹起した糖尿病マウスに薬物を投与
する方法が知られている（Fujiiet al.,Jpn.J.Pharmaco
l.,34,113（1984）。そこで、このモデルを用いて本化
合物の有用性を調べた。As a method for examining the usefulness of diapers for diabetes, a method of administering a drug to diabetic mice induced by streptozotocin is known (Fujiiet al., Jpn. J. Pharmaco.
l., 34 , 113 (1984). Therefore, the usefulness of the present compound was examined using this model.
詳細な結果については薬理試験の項で述べるが、本化
合物をマウスに投与したものは、コントロールと比較し
て明らかに血液中のグルコース量が減少しており、本化
合物が糖尿病の治療剤として有用であることが実証され
た。Although the detailed results are described in the section on pharmacological tests, the compound administered to mice showed a clear decrease in blood glucose level as compared to the control, indicating that this compound is useful as a therapeutic agent for diabetes It was proved that.
尚、本発明における糖尿病治療剤とは、糖尿病性網膜
症のように糖尿病に起因するいろいろな疾患の治療剤を
も包含するものである。The therapeutic agent for diabetes in the present invention includes therapeutic agents for various diseases caused by diabetes, such as diabetic retinopathy.
本化合物は経口投与、非経口投与のいずれでも投与す
ることができ、公知の製剤技術により錠剤、顆粒剤、散
剤、注射剤等の製剤とすることができる。The present compound can be administered either orally or parenterally, and can be made into tablets, granules, powders, injections and other preparations by known preparation techniques.
本化合物の投与量は症状、剤型、年令等によつて決め
られるが、経口投与の場合、通常１日10〜1000mgを１回
または数回に分けて投与すればよい。The dose of the compound is determined according to symptoms, dosage form, age and the like. In the case of oral administration, usually 10 to 1000 mg per day may be administered once or in several divided doses.
糖尿病に対する薬物の有用性を調べる方法として、ス
トレプトゾトシンで惹起した糖尿病マウスに薬物を投与
する方法が知られている（Fujiiet at.,Jpn.J.Pharmaco
l.,34,113（1984））。そこで、このモデルを用いて本
化合物の有用性を調べた。As a method of examining the usefulness of a drug for diabetes, a method of administering the drug to diabetic mice induced by streptozotocin is known (Fujiiet at., Jpn. J. Pharmaco.
l., 34 , 113 (1984)). Therefore, the usefulness of the present compound was examined using this model.
（実験方法） 上記の文献に準じ、本化合物の投与量が10mg/kgとな
るように餌に混ぜてICR系マウス（１群６匹）に投与
し、ストレプトゾトシンは生理食塩液に溶解したものを
投与開始より５日間40mg/kg腹腔内投与した。本化合物
投与８日および15日後にマウスより採血を行ない、血液
中のグルコース量を定量した。なお、コントロールとし
ては本化合物を投与せず、ストレプトゾトシンのみを投
与したものを用いた。(Experimental method) According to the above literature, this compound was mixed with food so that the dose was 10 mg / kg, and administered to ICR mice (6 mice per group). Streptozotocin dissolved in physiological saline was used. It was administered intraperitoneally at 40 mg / kg for 5 days from the start of administration. Blood was collected from the mice 8 and 15 days after administration of the compound, and the amount of glucose in the blood was quantified. As a control, a compound to which only the streptozotocin was administered without administering the present compound was used.
（結果） 得られた結果を表に示す。(Results) The obtained results are shown in the table.
表に示すように、本化合物を投与したものはコントロ
ールと比較して明らかに血液中のグルコース量が減少し
た。 As shown in the table, the administration of the present compound clearly reduced the amount of glucose in the blood as compared with the control.
「発明の効果」 薬理試験の結果で示されるように、本化合物は血液中
のグルコース量を減少させる作用を有することから、本
化合物が糖尿病治療剤として有用であることが明らかと
なつた。[Effect of the Invention] As shown in the results of the pharmacological test, the present compound has an effect of reducing the amount of glucose in blood, and thus it has been clarified that the present compound is useful as a therapeutic agent for diabetes.
Claims (1)
る糖尿病治療剤。(1) A therapeutic agent for diabetes comprising bucillamine or a salt thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27997790A JP2816499B2 (en) | 1990-10-17 | 1990-10-17 | Diabetes treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27997790A JP2816499B2 (en) | 1990-10-17 | 1990-10-17 | Diabetes treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04154721A JPH04154721A (en) | 1992-05-27 |
| JP2816499B2 true JP2816499B2 (en) | 1998-10-27 |
Family
ID=17618586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP27997790A Expired - Fee Related JP2816499B2 (en) | 1990-10-17 | 1990-10-17 | Diabetes treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2816499B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311868T1 (en) | 1999-06-21 | 2005-12-15 | Santen Pharmaceutical Co Ltd | MEDICINAL PRODUCTS FOR RHEUMATOID ARTHRITIS |
-
1990
- 1990-10-17 JP JP27997790A patent/JP2816499B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04154721A (en) | 1992-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vickers | Gammahydroxybutyric acid | |
| EP0750909A1 (en) | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence | |
| JP3852786B2 (en) | Bone atrophy improving agent | |
| GB2198942A (en) | Therapeutic composition for diabetic complications | |
| JP3415643B2 (en) | Drugs for muscular dystrophy | |
| JPH0352815A (en) | Remedy for intravascular blood coagulation syndrome | |
| JPH03170475A (en) | Therapeutic agent for combating depression | |
| JP2816499B2 (en) | Diabetes treatment | |
| JPH0352816A (en) | Remedy for nephritis | |
| EP0290817A2 (en) | A Use of oxetanocin for inhibiting HIV | |
| JPH06502155A (en) | How to treat demyelinating diseases | |
| EP0256629A2 (en) | Tolrestat or a salt thereof as an immuno-stimulating agent | |
| RU2404976C1 (en) | Agent to reduce alcohol addiction, pharmaceutical composition, method for making thereof, medicinal agent and method of treating | |
| US4731380A (en) | Tolerstat as an agent for diabetic periodontitis | |
| JP2816500B2 (en) | Anti-osteoporosis agent | |
| JPS61134315A (en) | Antipyretic and analgesic agent | |
| JPS6058726B2 (en) | Antiallergic, analgesic, and sedative agent containing purine derivatives as active ingredients | |
| JP2807535B2 (en) | Cataract treatment | |
| JP2542846B2 (en) | Antidiabetic agent | |
| US3198703A (en) | Method of producing sympathomimetic activity by isopropyl-2'-phenoxymethyl-2-imidazoline | |
| JPS6345371B2 (en) | ||
| JPS6050768B2 (en) | Antidiabetic agent containing 2,3-dihydroxypropyl ester of N-(7-chloro-4-quinolyl)anthranilic acid | |
| JP3066051B2 (en) | Hashimoto thyroiditis treatment | |
| JPH07223944A (en) | Therapeutic agent for inflammatory intestinal disease | |
| JPH05301816A (en) | Anti-aids agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |